Export afgerond — 

An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer

BACKGROUND. Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR-2) are believed to mediate angiogenesis in colorectal cancer (CRC). Ramucirumab (RAM; IMC-1121B) is a human IgG1 monoclonal antibody that inhibits VEGF ligand binding to VEGFR-2, inhibiting VEGFR-2 activation and signal...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Garcia-Carbonero, Rocio, Rivera, Fernando, Maurel, Joan, Ayoub, Jean-Pierre M., Moore, Malcolm J., Cervantes, Andres, Asmis, Timothy R., Schwartz, Jonathan D., Nasroulah, Federico, Ballal, Shaila, Tabernero, Josep
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: AlphaMed Press 2014
Onderwerpen:
Clinical Trial Results
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3983832/
https://ncbi.nlm.nih.gov/pubmed/24674871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0028
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items